A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid TumorsAdvanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction Cancer
- Interventions
- Drug: MRG002
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT04492488
- Locations
- 🇺🇸
University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath